Anavex Life Sciences Corp (FRA:12X1)
€ 3.495 0.164 (4.92%) Market Cap: 299.15 Mil Enterprise Value: 165.79 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 34/100

Anavex Life Sciences Corp. - Special Call Transcript

Oct 15, 2020 / 12:30PM GMT
Release Date Price: €5 (+34.41%)
Operator

Welcome to the ANAVEX 2-73-PDD-001 Study Call. My name is John. I'll be your operator for today's call. (Operator Instructions) And I will now turn the call over to Dr. Christopher Missling.

Christopher U. Missling
Anavex Life Sciences Corp. - Chairman, President, CEO & Secretary

Welcome, everyone. I am Christopher Missling, President and CEO of Anavex. And I'm here with Professor Dr. Dag Aarsland. Dr. Dag Aarsland is Professor and the Head of Department of Old Age Psychiatry at the Institute of Psychiatry, Psychology & Neuroscience, King's College London, U.K.

Professor Aarsland is also consultant psychiatrist at the Mental Health for Older Adults and dementia, South London; and mostly NHS Foundation Trust, where he leads the Parkinson Spectrum Memory Clinic.

Before beginning, please note that during this call the company will make some projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the SEC. These include, without limitation, the company's Form 10-K and 10-Q,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot